Core Viewpoint - Danah Biotechnology officially listed on the Beijing Stock Exchange, marking a significant milestone for the company specializing in early diagnosis of invasive fungal diseases and other pathogen detection products [1][4]. Company Overview - Founded in 2014, Danah Biotechnology focuses on the research, production, and sales of early diagnostic products for invasive fungal diseases and other pathogens, holding 91 domestic and international patents, 79 domestic registered products, and 102 CE certifications [5]. - The company has established five core technology platforms, creating a comprehensive automated, intelligent, and standardized product pipeline to meet diverse clinical testing and diagnostic needs [5]. Listing Details - The company issued 8 million new shares at a price of 17.10 yuan per share, opening at 93.70 yuan and reaching a high of 111.70 yuan on the first trading day, ultimately closing at 102.10 yuan, reflecting a 497.08% increase [4]. - The total trading volume was 67,900 hands, with a transaction value of 666.5 million yuan and a turnover rate of 94.25%, resulting in a total market capitalization of 5.655 billion yuan [4]. Future Plans - The net proceeds from the fundraising, after deducting issuance costs of 22.23 million yuan, are expected to be approximately 114.57 million yuan, which will be allocated to the headquarters construction project and new product development [8]. - The headquarters project in Tianjin has a total investment of 302 million yuan, with a construction period of 36 months and an approved capacity of 65.06 million tests [8]. - The new product development project aims to expand the product line based on existing technology platforms, focusing on research related to invasive fungal infections, respiratory pathogens, and gynecological infections, as well as the development of core raw materials and related detection equipment [8].
[新股]丹娜生物成功登陆北交所 侵袭性真菌病诊断试剂龙头起航新征程